Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Open Label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 Plus Entinostat in Advanced Renal Cell Carcinoma

NCT03501381 is registered in ClinicalTrials.gov with Roberto Pili as lead sponsor.

NCT NCT03501381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03501381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Open Label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 Plus Entinostat in Advanced Renal Cell Carcinoma
Lead sponsor
Roberto Pili
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 24, 2018
Completion date
April 30, 2024
Enrollment
46 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma